INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 330.88M USD | Liabilities, Current |
| Cash and equivalents | 214.41M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 267.19M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 492.00M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $330.88M | $214.41M | (m) | $267.19M | $492.00M | (m) |
| 2026-03-31 | (m) | $346.85M | $236.81M | (m) | $264.41M | $495.04M | (m) |
| 2025-12-31 | (m) | $455.98M | $235.05M | (m) | $278.85M | $492.74M | (m) |
| 2025-09-30 | (m) | $364.05M | $232.19M | (m) | $262.16M | $489.11M | (m) |
| 2025-06-30 | (m) | $929.81M | $217.91M | (m) | $284.51M | $465.13M | (m) |
| 2025-03-31 | (m) | $918.45M | $239.10M | (m) | $252.45M | $445.42M | (m) |
| 2024-12-31 | (m) | $922.13M | $246.38M | (m) | $272.37M | $429.09M | (m) |
| 2024-09-30 | (m) | $912.56M | $215.16M | (m) | $248.30M | $436.93M | (m) |
| 2024-06-30 | (m) | $328.32M | $215.24M | (m) | $271.15M | $421.77M | (m) |
| 2024-03-31 | (m) | $302.39M | $591.91M | (m) | $241.09M | $403.42M | (m) |
| 2023-12-31 | (m) | $306.98M | $276.40M | (m) | $259.33M | $389.61M | (m) |
| 2023-09-30 | (m) | $355.71M | $273.73M | (m) | $256.27M | $366.25M | (m) |
| 2023-06-30 | (m) | $377.50M | $309.19M | (m) | $258.66M | $354.29M | (m) |
| 2023-03-31 | (m) | $282.29M | $307.37M | (m) | $254.00M | $351.27M | (m) |
| 2022-12-31 | (m) | $320.91M | $456.66M | (m) | $263.46M | $324.58M | (m) |
| 2022-09-30 | (m) | $304.45M | $511.94M | (m) | $248.27M | $311.06M | (m) |
| 2022-06-30 | (m) | $295.60M | $447.15M | (m) | $237.36M | $320.21M | (m) |
| 2022-03-31 | (m) | $315.83M | $407.09M | (m) | $234.01M | $328.00M | (m) |
| 2021-12-31 | (m) | $340.02M | $513.45M | (m) | $231.83M | $317.39M | (m) |
| 2021-09-30 | (m) | $332.86M | $470.23M | (m) | $222.23M | $327.17M | (m) |
| 2021-06-30 | (m) | $318.76M | $397.41M | (m) | $229.82M | $323.62M | (m) |
| 2021-03-31 | (m) | $412.30M | $408.98M | (m) | $223.54M | $328.05M | (m) |
| 2020-12-31 | (m) | $401.01M | $470.17M | (m) | $225.53M | $310.12M | (m) |
| 2020-09-30 | (m) | $255.15M | $396.28M | (m) | $218.18M | $307.84M | (m) |
| 2020-06-30 | (m) | $212.41M | $360.98M | (m) | $179.14M | $358.76M | (m) |
| 2020-03-31 | (m) | $246.49M | $357.71M | (m) | $245.55M | $338.08M | (m) |
| 2019-12-31 | (m) | $331.31M | $198.91M | (m) | $275.30M | $316.05M | (m) |
| 2019-09-30 | (m) | $302.64M | $207.98M | (m) | $281.12M | $302.62M | (m) |
| 2019-06-30 | (m) | $315.11M | $176.08M | (m) | $296.51M | $296.50M | (m) |
| 2019-03-31 | (m) | $288.11M | $157.03M | (m) | $279.07M | $286.96M | (m) |
| 2018-12-31 | (m) | $262.55M | $138.84M | (m) | $265.74M | $280.35M | (m) |
| 2018-09-30 | (m) | $258.34M | $205.99M | (m) | $248.74M | $290.85M | (m) |
| 2018-06-30 | (m) | $233.34M | $183.77M | (m) | $258.38M | $290.52M | (m) |
| 2018-03-31 | (m) | $336.02M | $189.40M | (m) | $272.26M | $290.47M | (m) |
| 2017-12-31 | (m) | $348.91M | $174.94M | (m) | $251.80M | $296.33M | (m) |
| 2017-09-30 | (m) | $210.23M | $481.94M | (m) | $171.13M | $232.34M | (m) |
| 2017-06-30 | (m) | $177.88M | $154.60M | (m) | $171.32M | $234.68M | (m) |
| 2017-03-31 | (m) | $188.08M | $124.11M | (m) | $158.23M | $239.81M | (m) |
| 2016-12-31 | (m) | $123.60M | $102.06M | (m) | $148.19M | $217.26M | (m) |
| 2016-09-30 | (m) | $161.40M | $107.60M | (m) | $140.75M | $219.67M | (m) |
| 2016-06-30 | (m) | $149.83M | $86.80M | (m) | $145.57M | $220.44M | (m) |
| 2016-03-31 | (m) | $156.63M | $77.09M | (m) | $151.61M | $221.98M | (m) |
| 2015-12-31 | (m) | $139.13M | $48.13M | (m) | $132.24M | $211.43M | (m) |
| 2015-09-30 | (m) | $139.95M | $79.31M | (m) | $125.47M | $213.88M | (m) |
| 2015-06-30 | (m) | $155.75M | $131.30M | (m) | $134.55M | $241.84M | (m) |
| 2015-03-31 | (m) | $126.81M | $79.87M | (m) | $126.78M | $233.04M | (m) |
| 2014-12-31 | (m) | $126.03M | $71.99M | (m) | $131.92M | $237.11M | (m) |
| 2014-09-30 | (m) | $130.12M | $140.23M | (m) | $120.74M | $230.46M | (m) |
| 2014-06-30 | (m) | $126.90M | $137.16M | (m) | $118.26M | $223.63M | (m) |
| 2014-03-31 | (m) | $116.83M | $129.04M | (m) | $112.52M | $215.23M | (m) |
| 2013-12-31 | (m) | $119.38M | $120.61M | (m) | $118.14M | $213.43M | (m) |
| 2013-09-30 | (m) | $122.28M | $118.87M | (m) | $113.54M | $207.39M | (m) |
| 2013-06-30 | (m) | $109.34M | $98.64M | (m) | $114.75M | $195.46M | (m) |
| 2013-03-31 | (m) | $105.78M | $89.69M | (m) | $111.94M | $179.56M | (m) |
| 2012-12-31 | (m) | $106.93M | $96.94M | (m) | $114.92M | $171.81M | (m) |
| 2012-09-30 | (m) | $112.57M | $125.72M | (m) | $119.53M | $169.38M | (m) |
| 2012-06-30 | (m) | $112.25M | $75.47M | (m) | $115.57M | $172.54M | (m) |
| 2012-03-31 | (m) | $104.59M | $58.64M | (m) | $114.00M | $172.47M | (m) |
| 2011-12-31 | (m) | $101.87M | $100.81M | (m) | $118.13M | $171.26M | (m) |
| 2011-09-30 | (m) | $104.43M | $110.99M | (m) | $117.78M | $181.43M | (m) |
| 2011-06-30 | (m) | $118.01M | $137.28M | (m) | $116.18M | $174.46M | (m) |
| 2011-03-31 | (m) | $163.32M | $104.35M | (m) | $106.12M | $154.60M | (m) |
| 2010-12-31 | (m) | $200.03M | $128.76M | (m) | $106.00M | $146.93M | (m) |
| 2010-09-30 | (m) | $102.70M | $82.83M | (m) | $107.15M | $147.97M | (m) |
| 2010-06-30 | (m) | $85.64M | $93.62M | (m) | $97.78M | $143.25M | (m) |
| 2010-03-31 | (m) | (m) | $81.67M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $156.73M | $71.89M | (m) | $103.23M | $140.24M | (m) |
| 2009-09-30 | (m) | (m) | $106.75M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $138.72M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $183.55M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $57.34M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |